Qingfeng Li
Impact in
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
- Viral gastroenteritis research and epidemiology
-
- Long-Term Effects of COVID-19
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- COVID-19 Clinical Research Studies 4
- Tuberculosis Research and Epidemiology 3
- HIV/AIDS drug development and treatment 2
-
- Biochemical and Molecular Research 2
- Co-authors
- Yilan Zeng (2 shared papers)Na Zhang (1 shared paper)Dan Wang (1 shared paper)Hong Chen (1 shared paper)Hong Xu (1 shared paper)Ru Liu (1 shared paper)Ming Yang (1 shared paper)Piet Herdewijn (5 shared papers)
In The Last Decade
Qingfeng Li
14 papers receiving 279 citations
Peers
Comparison fields: 5 of 59
- Infectious Diseases 187
- Neurology 54
- Internal Medicine 4
- Toxicology 4
- Oncology 29
Countries citing papers authored by Qingfeng Li
This map shows the geographic impact of Qingfeng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingfeng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingfeng Li more than expected).
Fields of papers citing papers by Qingfeng Li
This network shows the impact of papers produced by Qingfeng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingfeng Li. The network helps show where Qingfeng Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Qingfeng Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 128 | |
| 2 | 2022 | 37 | |
| 3 | 2017 | 17 | |
| 4 | 2020 | 16 | |
| 5 | 2019 | 16 | |
| 6 | 2022 | 15 | |
| 7 | 2021 | 15 | |
| 8 | 2021 | 11 | |
| 9 | 2020 | 7 | |
| 10 | 2022 | 6 | |
| 11 | 2020 | 6 | |
| 12 | 2021 | 5 | |
| 13 | 2019 | 2 | |
| 14 | 2020 | 2 | |
| 15 | 2024 | 0 |
About Qingfeng Li
Qingfeng Li is a scholar working on Infectious Diseases, Molecular Biology, Organic Chemistry, Epidemiology and Neurology, having authored 15 papers that have together received 283 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (4 papers), Tuberculosis Research and Epidemiology (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), HIV/AIDS drug development and treatment (2 papers), Long-Term Effects of COVID-19 (2 papers), Biochemical and Molecular Research (2 papers) and Cyclopropane Reaction Mechanisms (1 paper). The work is most often cited by research in Infectious Diseases (187 citations), Neurology (54 citations), Internal Medicine (4 citations), Toxicology (4 citations) and Oncology (29 citations). Qingfeng Li has collaborated with scholars based in China, Belgium and Australia. Frequent co-authors include Yilan Zeng, Na Zhang, Dan Wang, Hong Chen, Hong Xu, Ru Liu, Ming Yang, Piet Herdewijn, Dirk Daelemans and Leentje Persoons. Their work appears in journals such as Tetrahedron, Medicine, International Immunopharmacology, Frontiers in Microbiology and Diabetology & Metabolic Syndrome.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.